Pilot study of dovitinib in patients with von Hippel-Lindau disease

Von Hippel-Lindau (VHL) disease is an autosomal dominant disease occurring in 1 in 35,000 births and leads to an increased risk of a phenotypically diverse array of tumor types including, but not limited to, clear cell renal cell carcinoma (ccRCC) and hemangioblastomas (HBs). Previous studies of pat...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Oncotarget
Huvudupphovsmän: Pilié, Patrick, Hasanov, Elshad, Matin, Surena F., Woodson, Ashley H. Henriksen, Marcott, Valerie D., Bird, Shelly, Slack, Rebecca S., Fuller, Gregory N., McCutcheon, Ian E., Jonasch, Eric
Materialtyp: Artigo
Språk:Inglês
Publicerad: Impact Journals LLC 2018
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5955100/
https://ncbi.nlm.nih.gov/pubmed/29805741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25171
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk